SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 368 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $103,697,099 | -7.3% | 855,444 | -12.4% | 0.01% | 0.0% |
Q2 2023 | $111,811,671 | -8.8% | 976,350 | +9.8% | 0.01% | -15.4% |
Q1 2023 | $122,600,613 | +107.0% | 889,506 | +94.6% | 0.01% | +85.7% |
Q4 2022 | $59,224,928 | +35.2% | 457,053 | +15.3% | 0.01% | +16.7% |
Q3 2022 | $43,803,000 | +39.9% | 396,267 | -5.1% | 0.01% | +50.0% |
Q2 2022 | $31,310,000 | +8.2% | 417,706 | +12.7% | 0.00% | 0.0% |
Q1 2022 | $28,945,000 | +35.3% | 370,516 | +56.0% | 0.00% | +33.3% |
Q4 2021 | $21,387,000 | -31.8% | 237,503 | -30.0% | 0.00% | -25.0% |
Q3 2021 | $31,375,000 | +24.3% | 339,269 | +4.5% | 0.00% | +33.3% |
Q2 2021 | $25,242,000 | +75.9% | 324,696 | +68.6% | 0.00% | +50.0% |
Q1 2021 | $14,354,000 | -71.6% | 192,601 | -35.0% | 0.00% | -75.0% |
Q4 2020 | $50,525,000 | +76.8% | 296,356 | +45.6% | 0.01% | +33.3% |
Q3 2020 | $28,579,000 | -15.8% | 203,511 | -3.9% | 0.01% | -25.0% |
Q2 2020 | $33,942,000 | +1.9% | 211,680 | -37.8% | 0.01% | -11.1% |
Q1 2020 | $33,309,000 | -10.8% | 340,511 | +17.6% | 0.01% | 0.0% |
Q4 2019 | $37,349,000 | +137.7% | 289,429 | +38.7% | 0.01% | +125.0% |
Q3 2019 | $15,713,000 | -62.3% | 208,611 | -24.0% | 0.00% | -63.6% |
Q2 2019 | $41,695,000 | +112.9% | 274,400 | +67.0% | 0.01% | +83.3% |
Q1 2019 | $19,583,000 | +7.3% | 164,305 | -1.7% | 0.01% | +20.0% |
Q4 2018 | $18,244,000 | -40.1% | 167,182 | -11.3% | 0.01% | -37.5% |
Q3 2018 | $30,457,000 | -25.7% | 188,575 | -39.2% | 0.01% | -27.3% |
Q2 2018 | $41,002,000 | +5.9% | 310,206 | -40.6% | 0.01% | 0.0% |
Q1 2018 | $38,719,000 | -16.0% | 522,584 | -36.9% | 0.01% | -15.4% |
Q4 2017 | $46,072,000 | +289.0% | 828,037 | +217.1% | 0.01% | +225.0% |
Q3 2017 | $11,844,000 | +97.2% | 261,122 | +46.5% | 0.00% | +100.0% |
Q2 2017 | $6,007,000 | -46.6% | 178,184 | -53.1% | 0.00% | 0.0% |
Q1 2017 | $11,256,000 | -2.0% | 380,220 | -9.2% | 0.00% | 0.0% |
Q4 2016 | $11,482,000 | -61.3% | 418,568 | -13.4% | 0.00% | -80.0% |
Q3 2016 | $29,695,000 | +60.9% | 483,547 | -50.0% | 0.01% | +42.9% |
Q2 2016 | $18,455,000 | +112.2% | 967,727 | +117.1% | 0.01% | +133.3% |
Q1 2016 | $8,698,000 | +68.5% | 445,678 | +233.1% | 0.00% | +50.0% |
Q4 2015 | $5,162,000 | +47.1% | 133,785 | +22.4% | 0.00% | +100.0% |
Q3 2015 | $3,510,000 | -4.7% | 109,308 | -9.7% | 0.00% | 0.0% |
Q2 2015 | $3,684,000 | +280.2% | 121,061 | +66.0% | 0.00% | – |
Q1 2015 | $969,000 | -6.8% | 72,938 | +1.5% | 0.00% | – |
Q4 2014 | $1,040,000 | -51.4% | 71,836 | -29.1% | 0.00% | -100.0% |
Q3 2014 | $2,138,000 | -34.7% | 101,329 | -7.7% | 0.00% | 0.0% |
Q2 2014 | $3,272,000 | +56.8% | 109,776 | +26.4% | 0.00% | 0.0% |
Q1 2014 | $2,087,000 | +79.4% | 86,846 | +52.2% | 0.00% | – |
Q4 2013 | $1,163,000 | -92.8% | 57,064 | -83.2% | 0.00% | -100.0% |
Q3 2013 | $16,050,000 | +472.4% | 339,820 | +360.9% | 0.01% | +700.0% |
Q2 2013 | $2,804,000 | – | 73,733 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |